Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Sign Up to like & getrecommendations! Published in 2017 at "European urology"
DOI: 10.1016/j.eururo.2017.03.007
Abstract: In the COU-AA-302 trial, abiraterone acetate plus prednisone significantly increased overall survival for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). Limited information exists regarding response to subsequent androgen signaling-directed therapies following abiraterone acetate plus… read more here.
Keywords: plus prednisone; abiraterone; abiraterone acetate; acetate plus ... See more keywords
Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study
Sign Up to like & getrecommendations! Published in 2020 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyaa030
Abstract: Abstract Background LATITUDE was a randomized, double-blind, international and phase 3 study of abiraterone acetate plus prednisone in patients with high-risk metastatic hormone-naïve prostate cancer. In the first interim analysis of LATITUDE (clinical cutoff date:… read more here.
Keywords: plus prednisone; analysis; abiraterone acetate; acetate plus ... See more keywords
Sequential ADT and abiraterone acetate plus prednisone versus combined ADT with abiraterone acetate plus prednisone for metastatic castration-sensitive prostate cancer: A propensity score-matched study.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e17075
Abstract: e17075 Background: Previous studies showed that combination of androgen deprivation therapy (ADT) with abiraterone acetate plus prednisone was associated with longer survival than ADT alone in patients with metastatic castration-sensitive prostate cancer (mCSPC). The aim… read more here.
Keywords: adt abiraterone; acetate plus; acetate; plus prednisone ... See more keywords
Efficacy and safety of darolutamide versus abiraterone acetate plus prednisone in combination with ADT for mHSPC: a real-world clinical retrospective study
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2025.1608339
Abstract: Introduction Effective treatment during the metastatic hormone-sensitive prostate cancer (mHSPC) stage is crucial for delaying disease progression. Due to the lack of a head-to-head comparison of darolutamide (DARO) and abiraterone acetate plus prednisone (AAP) doublet… read more here.
Keywords: time; acetate plus; daro; plus prednisone ... See more keywords